Contemporary lymphoma radiation target volumes that rely on post-systemic therapy imaging do not have standardised nomenclature. A forum of radiation oncology lymphoma leaders from the National Clinical Trials Network groups (NRG Oncology, Children's Oncology Group, SWOG Cancer Research Network, Alliance for Clinical Trials in Oncology, Eastern Cooperative Oncology Group–American College of Radiology Imaging Network Cancer Research Group, and the Canadian Cancer Trials Group) was convened and established standardised nomenclature for these volumes in the autumn of 2024. Involved-site radiotherapy includes the full cranial–caudal extent of prechemotherapy disease and takes into account axial anatomical changes only. Residual site radiotherapy targets only the postchemotherapy CT-anatomical mass. PET-directed radiotherapy exclusively targets PET-positive disease and includes three types: PET-directed involved site radiotherapy using the superior–inferior aspect of prechemotherapy involved disease sites that remain PET-avid on post-treatment imaging; PET-directed residual site radiotherapy using only the postchemotherapy CT-anatomical residual mass that contains the PET-avid lesion on post-treatment imaging, without excluding sites that had complete metabolic response; and PET-directed residual PET radiotherapy using only the PET-avid focus, irrespective of the corresponding adjacent non-PET-avid CT-anatomical disease surrounding it.

中文翻译：

---

淋巴瘤试验的放射靶区命名法：来自美国国家临床试验网络小组的共识建议


依赖于全身治疗后成像的当代淋巴瘤放射靶区体积没有标准化的命名法。来自国家临床试验网络小组（NRG 肿瘤学、儿童肿瘤学组、SWOG 癌症研究网络、肿瘤学临床试验联盟、东部肿瘤合作组-美国放射学成像网络癌症研究组和加拿大癌症试验组）的放射肿瘤学淋巴瘤领导者论坛于 2024 年秋季召开，并为这些卷建立了标准化命名法。受累部位放疗包括化疗前疾病的整个颅尾范围，并且仅考虑轴向解剖变化。残余部位放疗仅针对化疗后 CT 解剖肿块。PET 靶向放疗仅针对 PET 阳性疾病，包括三种类型： PET 靶向受累部位放疗，使用化疗前受累部位的上下侧，这些部位在治疗后成像上保持 PET 亲和力;PET 定向残余部位放疗仅使用化疗后 CT 解剖残余肿块，该肿块在治疗后影像学上包含 PET 亲和病灶，而不排除具有完全代谢反应的部位;和 PET 定向残余 PET 放疗仅使用 PET 亲和病灶，而不考虑其周围相应的相邻非 PET 亲和性 CT 解剖疾病。